gatifloxacin has been researched along with carbostyril in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (37.04) | 18.2507 |
| 2000's | 32 (59.26) | 29.6817 |
| 2010's | 2 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, H; Fukuda, H; Hirai, K; Hosaka, M; Tomizawa, H; Yasue, T | 1 |
| Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R | 1 |
| Ishida, R; Kusajima, H; Nakashima, M; Ohkubo, H; Uematsu, T; Umemura, K | 1 |
| Mitsuhashi, S; Wakabayashi, E | 1 |
| Saito, H; Sato, K; Tomioka, H | 1 |
| Hosaka, M; Kinoshita, S; Nishino, T; Otsuki, M; Toyama, A | 1 |
| Chida, K; Hayakawa, H; Iwata, M; Kitazawa, H; Sato, A | 2 |
| Ishida, R; Kosuge, K; Kusajima, H; Masuda, Y; Nakashima, M; Ooie, T; Uchida, H; Uematsu, T | 1 |
| Fukuda, H; Hosaka, M; Kusajima, H; Oomori, Y; Shinoda, H; Yamamoto, T | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Kishimoto, T; Matsushima, T; Miyashita, N; Nakajima, M; Niki, Y | 1 |
| Kato, H; Kato, N; Tanaka-Bandoh, K; Ueno, K; Watanabe, K | 1 |
| Bauernfeind, A | 1 |
| Miyazaki, S; Tateda, K; Tomizawa, H; Yamaguchi, K | 1 |
| Fukuda, H; Hiramatsu, K; Hori, S | 1 |
| Appelbaum, PC; Ednie, LM; Jacobs, MR | 1 |
| Biedenbach, DJ; Croco, MA; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Beach, ML; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Schaeffer, AJ | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Anderegg, TR; Biedenbach, DJ; Jones, RN | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Otsu, Y; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Bébéar, C; Bébéar, CM; Pereyre, S; Renaudin, H | 1 |
| Gonoi, T; Saraya, A; Seino, S; Yokokura, M | 1 |
| Frisbee-Hume, S; LeBlanc, B; Rolston, KV; Streeter, H; Vaziri, I | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Hasegawa, M; Kobayashi, I; Koyama, H; Matsuzaki, K; Sato, Y; Watabe, E | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Kassab, NM; Kedor-Hackmam, ER; Santoro, MI; Singh, AK | 1 |
| Abdel Ghani, NT; El Ries, MA; El-Shall, MA; Wassel, AA | 1 |
| Wang, S; Wang, Y; Yu, K | 1 |
| Hori, S; Kawamura, M; Kizu, J | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Baeyens, WR; Ouyang, J; Yang, Y; Zhao, H; Zhou, S | 1 |
| Drlica, K; Malik, M; Zhao, X | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Inagaki, N; Kawasaki, Y; Nagashima, K; Seino, Y; Takahashi, A; Ueno, H; Yamada, C; Yamada, Y | 1 |
| Jain, M; Jayadev, S; Mishra, B; Patel, PR; Solanki, M; Soni, R; Srivastava, BK; Valani, D | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Kozai, S; Ohashi, Y; Sakaki, H; Suzuki, T; Tajika, T; Wada, T | 1 |
| Horstkotte, MA; Knobloch, JK; Mack, D; Rohde, H; Von Osten, H | 1 |
| Bosgelmez-Tinaz, G; Coskun-Ari, FF | 1 |
| Baeyens, WR; Fei, G; He, L; Huang, C; Ouyang, J; Wang, Y | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Hsu, MC; Leunk, R; Makin, K; Roychoudhury, S; Twinem, T | 1 |
1 review(s) available for gatifloxacin and carbostyril
| Article | Year |
|---|---|
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
1 trial(s) available for gatifloxacin and carbostyril
| Article | Year |
|---|---|
Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
Topics: Adult; Anti-Infective Agents; Biotransformation; Blood Proteins; Creatinine; Feces; Fluoroquinolones; Food-Drug Interactions; Gatifloxacin; Half-Life; Humans; Male; Piperazines; Probenecid; Quinolones; Renal Agents; Saliva | 1995 |
52 other study(ies) available for gatifloxacin and carbostyril
| Article | Year |
|---|---|
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Tissue Distribution | 1992 |
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cell Death; Cricetinae; Disease Models, Animal; Erythromycin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mesocricetus; Minocycline; Mycoplasma pneumoniae; Piperazines; Pneumonia, Mycoplasma; Quinolones | 1994 |
A new antimicrobial quinolone (AM-1155) analysed in hair as an index of drug exposure and as a time-marker.
Topics: Adult; Anti-Infective Agents; Biomarkers; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Hair; Humans; Male; Piperazines; Quinolones; Spectrometry, Fluorescence | 1993 |
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Humans; Japan; Microbial Sensitivity Tests; Mutation; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1994 |
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Topics: Animals; Anti-Infective Agents; Female; Fluoroquinolones; Gatifloxacin; Intracellular Fluid; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Piperazines; Quinolones | 1993 |
Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Time Factors | 1995 |
Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; Lung; Lymphoid Tissue; Male; Piperazines; Pseudomonas Infections; Quinolones; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections | 1995 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; Immunoglobulin G; Male; Piperazines; Pseudomonas Infections; Quinolones; Rats; Rats, Sprague-Dawley; Tracheal Diseases | 1997 |
Uptake and intracellular activity of AM-1155 in phagocytic cells.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Humans; Kinetics; Macrophages; Mice; Neutrophils; Phagocytes; Piperazines; Quinolones; Staphylococcus aureus | 1996 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Topics: Animals; Anti-Infective Agents; Chlamydia; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Chlamydophila psittaci; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Male; Mice; Microbial Sensitivity Tests; Piperazines; Pneumonia, Bacterial; Quinolones | 1997 |
Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
Topics: Animals; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Cecum; Fluoroquinolones; Gatifloxacin; Granuloma; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Rats | 1997 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Penicillin Resistance; Piperazines; Pneumococcal Infections; Quinolones; Streptococcus pneumoniae; Survival Rate | 1998 |
Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
Topics: Anti-Infective Agents; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Piperazines; Quinolones; Staphylococcus aureus; Transformation, Bacterial | 1998 |
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones | 1998 |
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Humans; Legionella; Legionella pneumophila; Legionellosis; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1998 |
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Naphthyridines; North America; Quinolones; South America | 1998 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Guidelines as Topic; Haemophilus influenzae; Humans; Indoles; Microbial Sensitivity Tests; Quality Control; Quinolones; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolones; Survival Analysis | 2003 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma Infections; Naphthyridines; Quinolones | 2004 |
Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Cells, Cultured; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Islets of Langerhans; Levofloxacin; Mice; Ofloxacin; Patch-Clamp Techniques; Potassium Channels; Quinolones | 2004 |
In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
Topics: Anti-Bacterial Agents; Enterococcus; Fermentation; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Neutropenia; Quinolones; Staphylococcus; Streptococcus | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
[Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Quinolones | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibiotics in pharmaceutical preparations by high-performance liquid chromatography.
Topics: Anti-Bacterial Agents; Calibration; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Ethylamines; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Models, Chemical; Models, Statistical; Ofloxacin; Pefloxacin; Pharmaceutical Preparations; Quinolones; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets; Temperature; Time Factors | 2006 |
Electrochemical adsorptive behavior of some fluoroquinolones at carbon paste electrode.
Topics: Adsorption; Anti-Infective Agents; Carbon; Chromatography, High Pressure Liquid; Electrochemistry; Electrodes; Fluoroquinolones; Gatifloxacin; Quinolones | 2005 |
Vibrational spectra study on quinolones antibiotics.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Molecular Structure; Ofloxacin; Quinolones; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Vibration | 2006 |
Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice.
Topics: Animals; Blood Glucose; Enoxacin; Fluoroquinolones; Gatifloxacin; Hypoglycemia; Male; Mice; Quinolones | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
Chiral separation of four fluoroquinolone compounds using capillary electrophoresis with hydroxypropyl-beta-cyclodextrin as chiral selector.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Electrophoresis, Capillary; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Molecular Structure; Ofloxacin; Oxazines; Quinolones; Stereoisomerism | 2006 |
Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones.
Topics: Amino Acid Substitution; Chromosomes, Bacterial; Dimerization; DNA Fragmentation; DNA Gyrase; DNA, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Quinolones | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis.
Topics: Animals; Anti-Infective Agents; Blood Glucose; Cell Line, Tumor; Cell Separation; Fluoroquinolones; Gatifloxacin; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Antagonists; Insulin Secretion; Insulinoma; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Quinolones; RNA, Messenger | 2006 |
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Models, Chemical; Molecular Conformation; Pyridines; Quinolones | 2007 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Biological Availability; Disease Progression; Endophthalmitis; Enterococcus faecalis; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Male; Ofloxacin; Ointments; Ophthalmic Solutions; Quinolones; Rabbits | 2008 |
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Prosthesis-Related Infections; Quinolines; Quinolones; Staphylococcal Infections; Staphylococcus epidermidis | 2008 |
grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Electrophoresis, Agar Gel; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Methicillin Resistance; Mutation; Polymerase Chain Reaction; Quinolones; Staphylococcus aureus; Trans-Activators | 2008 |
Enhanced separation of seven quinolones by capillary electrophoresis with silica nanoparticles as additive.
Topics: Buffers; Electrophoresis, Capillary; Fleroxacin; Fluoroquinolones; Gatifloxacin; Nanoparticles; Ofloxacin; Oxazines; Quinolones; Silicon Dioxide | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Streptococcus pneumoniae; Structure-Activity Relationship | 2016 |